cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Alnylam Pharmaceuticals Inc
9 own
12 watching
Current Price
$0
$1.87
(0.98%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
23,659.21M
52-Week High
52-Week High
242.97
52-Week Low
52-Week Low
122.57
Average Volume
Average Volume
0.11M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization23,659.21M
icon52-Week High242.97
icon52-Week Low122.57
iconAverage Volume0.11M
iconDividend Yield--
iconP/E Ratio--
What does the Alnylam Pharmaceuticals Inc do?
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. Its pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis (ATTR); Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia. Its early stage clinical programs include Givosiran that is in Phase I trial to treat acute hepatic porphyrias; ALN-CC5 for the treatment of complement-mediated diseases; ALN-GO1 to treat primary hyperoxaluria 1; ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; and ALN-HBV for the treatment of Hepatitis B virus. The company has strategic alliances and collaboration agreements primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc.; The University of British Columbia; and Acuitas Therapeutics Inc.; and Arbutus Biopharma Corporation. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Alnylam Pharmaceuticals Inc make?
News & Events about Alnylam Pharmaceuticals Inc.
Ticker Report
1month ago
Research analysts at Sumitomo Mitsui Financial Group began coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY Get Rating) in a report released on Wednesday, Marketbeat reports. The brokerage set a neutral rating and a $220.00 price target on the biopharmaceutical ...
Benzinga
2 months ago
read more...
Insider Monkey
3 months ago
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2022 Earnings Call Transcript February 23, 2023 Operator: Thank you for standing by and welcome to the Alnylam Pharmaceuticals Fourth Quarter 2022 Financial Results Conference Call. As a reminder todays conference call is being recorded. I would now ...
Business Wire
3 months ago
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2022 and reviewed recent business highlights. 2022 was another year of strong progress at Alnylam, including...
Business Wire
5 months ago
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi (RNA interference) therapeutics company, announced today that the Company has submitted a Clinical Trial Authorization (CTA) application to Health Canada to initiate a Phase 1/2 study of ALN-KHK, an investigational RNAi therapeutic...
Frequently Asked Questions
Frequently Asked Questions
What is Alnylam Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Alnylam Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Alnylam Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Alnylam Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Alnylam Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Alnylam Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Alnylam Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Alnylam Pharmaceuticals Inc?
plus_minus_icon
What percentage is Alnylam Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Alnylam Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$1.87
(0.98%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc.
$12.87
$0.08 (0.61 %)
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$41.54
$-0.12 (-0.28 %)
Editas Medicine Inc.
Editas Medicine Inc.
$9.65
$0.05 (0.57 %)
Catalent, Inc.
Catalent, Inc.
$39.83
$0.00 (0.00 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc.
$12.87
$0.08 (0.61 %)
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$41.54
$-0.12 (-0.28 %)
Editas Medicine Inc.
Editas Medicine Inc.
$9.65
$0.05 (0.57 %)
Catalent, Inc.
Catalent, Inc.
$39.83
$0.00 (0.00 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00